Department of Oncology
Shanu Modi has not added Biography.
If you are Shanu Modi and would like to personalize this page please email our Author Liaison for assistance.
An update on epidermal growth factor receptor inhibitors.
Current oncology reports Jan, 2002 | Pubmed ID: 11734113
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2002 | Pubmed ID: 12202668
Single-agent gemcitabine in the treatment of advanced breast cancer.
Clinical breast cancer Jan, 2004 | Pubmed ID: 14754466
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
Breast cancer research and treatment Mar, 2005 | Pubmed ID: 15803362
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Clinical breast cancer Apr, 2005 | Pubmed ID: 15899073
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
Cancer Oct, 2005 | Pubmed ID: 16134178
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Cancer investigation , 2005 | Pubmed ID: 16203655
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Clinical breast cancer Aug, 2006 | Pubmed ID: 16942645
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec, 2007 | Pubmed ID: 18048823
Preoperative chemotherapy for breast cancer: miracle or mirage?
JAMA Dec, 2007 | Pubmed ID: 18073362
HER2 breast cancer therapies: a review.
Biologics : targets & therapy , 2009 | Pubmed ID: 19707416
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Clinical breast cancer Feb, 2010 | Pubmed ID: 20133256
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jun, 2010 | Pubmed ID: 20421541
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2011 | Pubmed ID: 21350003
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Clinical cancer research : an official journal of the American Association for Cancer Research Aug, 2011 | Pubmed ID: 21558407
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug, 2011 | Pubmed ID: 21730267
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Journal of clinical pharmacology May, 2012 | Pubmed ID: 21953571
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.
Biochimica et biophysica acta Mar, 2012 | Pubmed ID: 22062686
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.
Expert opinion on drug discovery May, 2011 | Pubmed ID: 22400044
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Cancer Dec, 2012 | Pubmed ID: 22648179
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2012 | Pubmed ID: 22649126
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2012 | Pubmed ID: 22781552
HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Advances in pharmacology (San Diego, Calif.) , 2012 | Pubmed ID: 22959035
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2012 | Pubmed ID: 23092874
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer.
Cancer prevention research (Philadelphia, Pa.) May, 2013 | Pubmed ID: 23531446
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.
Breast cancer research and treatment May, 2013 | Pubmed ID: 23580070
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.
Nuclear medicine communications Dec, 2013 | Pubmed ID: 24100444
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Clinical breast cancer Jun, 2014 | Pubmed ID: 24512858
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Expert opinion on investigational drugs May, 2014 | Pubmed ID: 24669860
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2014 | Pubmed ID: 24799465
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul, 2014 | Pubmed ID: 24799487
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
Breast cancer research and treatment Jul, 2014 | Pubmed ID: 24929675
Adriana D. Corben*,1,
Mohammad M. Uddin*,2,
Brooke Crawford3,
Mohammad Farooq4,
Shanu Modi5,
John Gerecitano5,
Gabriela Chiosis2,
Mary L. Alpaugh6
1Department of Pathology, Memorial Sloan Kettering Cancer Center,
2Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center,
3Department of Radiology, Weill Cornell Medical College,
4Department of Medicine, Memorial Sloan Kettering Cancer Center,
5Department of Oncology, Memorial Sloan Kettering Cancer Center,
6Department of Surgery, Memorial Sloan Kettering Cancer Center
Copyright © 2024 MyJoVE Corporation. Alle Rechte vorbehalten